Proof-of-mechanism based on target engagement and modulation of gene expression following treatment with SY-1365, a first-in-class selective CDK7 inhibitor in Phase 1 patients with advanced cancer
EUROPEAN JOURNAL OF CANCER（2018）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined